Professor Nicholas Turner has been recognised with a prestigious Fellowship of the Academy of Medical Sciences for his excellence in breast cancer research and outstanding contribution to the field.

Researchers at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, have been awarded a prestigious, National Institute for Health Research Programme (NIHR) grant that could revolutionise prostate cancer care.=

Targeting a molecule on the surface of immune cells could offer an exciting new way to treat prostate cancer by reawakening the immune response against it.

A single dose of a Covid-19 vaccine triggers an immune response in around 70 per cent of patients with myeloma – suggesting that it does provide protection against the virus.

Immunotherapy together with an experimental cancer drug could offer a new way of treating some patients with aggressive brain cancers, promising early results from a Phase I trial suggest.

Read about three trials of exciting new cancer drugs that demonstrate the joint ‘bench to bedside’ approach of The Royal Marsden and the ICR.

The Consultant Head and Neck Surgeon at The Royal Marsden and Director of the new International Centre for Recurrent Head & Neck Cancer (IReC) explains the centre’s aims.

A drug discovered at The Institute of Cancer Research, London that could counteract drug resistance in patients with cancers including acute myeloid leukaemia has entered a phase I clinical trial at The Royal Marsden NHS Foundation Trust.

A combination of three drugs is safe and shows signs of effectiveness in treating some patients with previously treated advanced breast cancer, a clinical trial shows.

Cancers that are resistant to radiotherapy could be rendered susceptible through treatment with immunotherapy, a new study supported by the NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London suggests.